• Skip to main content
  • Skip to secondary menu
  • Skip to primary sidebar
  • Skip to secondary sidebar
  • Skip to footer

  • Opinion
  • Health IT
    • Behavioral Health
    • Care Coordination
    • EMR/EHR
    • Interoperability
    • Patient Engagement
    • Population Health Management
    • Revenue Cycle Management
    • Social Determinants of Health
  • Digital Health
    • AI
    • Blockchain
    • Precision Medicine
    • Telehealth
    • Wearables
  • Startups
  • M&A
  • Value-based Care
    • Accountable Care (ACOs)
    • Medicare Advantage
  • Life Sciences
  • Research

AccessDX Acquires 2bPrecise from Allscripts for Actionable Precision Medicine Insights

by Jasmine Pennic 08/25/2021 Leave a Comment

  • LinkedIn
  • Twitter
  • Facebook
  • Email
  • Print
AccessDX Acquires 2bPrecise from Allscripts for Actionable Precision Medicine Insights

What You Should Know:

– AccessDX, a leading diagnostic laboratory, and diagnostic technology company has acquired 2bPrecise, a genomic and healthcare informatics innovator, from Allscripts Healthcare Solutions. This merger comes as advances in genetic research and medicine have driven skyrocketing demand for genetic testing, data, and insights by healthcare providers, laboratories, and consumers around the world. Financial details of the acquisition were not disclosed.

– Hospitals, health systems, and practices are clamoring for access to genetic testing and the informatic insights and workflows required to make practical use of that data in patient care. Together, 2bPrecise and AccessDX will offer a complete solution to drive the next generation of precision medicine, making data and insights easily accessible and usable across the healthcare continuum.

– The combination will create the most advanced and complete precision medicine solution available in the market today and will help drive broad adoption across a wide range of specialties. AccessDX offers a comprehensive set of diagnostic services and technology solutions. 2bPrecise takes genetic testing data and delivers point-of-care genetic insights within the EHR workflow. Together, they will give providers easy access to advanced genetic testing and enable them to quickly leverage that data to identify patients at risk for heritable conditions and drug-gene interactions, empowering them to make more precise diagnoses, and identify the most optimal therapies. 

  • LinkedIn
  • Twitter
  • Facebook
  • Email
  • Print

Tagged With: 2bPrecise, Allscripts, Healthcare Mergers & Acquisitions, Precision Medicine

Tap Native

Get in-depth healthcare technology analysis and commentary delivered straight to your email weekly

Reader Interactions

Primary Sidebar

Subscribe to HIT Consultant

Latest insightful articles delivered straight to your inbox weekly.

Submit a Tip or Pitch

Featured Insights

2025 EMR Software Pricing Guide

2025 EMR Software Pricing Guide

Featured Interview

Paradigm Shift in Diabetes Care with Studio Clinics: Q&A with Reach7 Founder Chun Yong

Most-Read

Medtronic to Separate Diabetes Business into New Standalone Company

Medtronic to Separate Diabetes Business into New Standalone Company

White House, IBM Partner to Fight COVID-19 Using Supercomputers

HHS Sets Pricing Targets for Trump’s EO on Most-Favored-Nation Drug Pricing

23andMe to Mine Genetic Data for Drug Discovery

Regeneron to Acquire Key 23andMe Assets for $256M, Pledges Continuity of Consumer Genome Services

CureIS Healthcare Sues Epic: Alleges Anti-Competitive Practices & Trade Secret Theft

The Evolving Role of Physician Advisors: Bridging the Gap Between Clinicians and Administrators

The Evolving Physician Advisor: From UM to Value-Based Care & AI

UnitedHealth Group Names Stephen Hemsley CEO as Andrew Witty Steps Down

UnitedHealth CEO Andrew Witty Steps Down, Stephen Hemsley Returns as CEO

Omada Health Files for IPO

Omada Health Files for IPO

Blue Cross Blue Shield of Massachusetts Launches "CloseKnit" Virtual-First Primary Care Option

Blue Cross Blue Shield of Massachusetts Launches “CloseKnit” Virtual-First Primary Care Option

Osteoboost Launches First FDA-Cleared Prescription Wearable Nationwide to Combat Low Bone Density

Osteoboost Launches First FDA-Cleared Prescription Wearable Nationwide to Combat Low Bone Density

2019 MedTech Breakthrough Award Category Winners Announced

MedTech Breakthrough Announces 2025 MedTech Breakthrough Award Winners

Secondary Sidebar

Footer

Company

  • About Us
  • Advertise with Us
  • Reprints and Permissions
  • Submit An Op-Ed
  • Contact
  • Subscribe

Editorial Coverage

  • Opinion
  • Health IT
    • Care Coordination
    • EMR/EHR
    • Interoperability
    • Population Health Management
    • Revenue Cycle Management
  • Digital Health
    • Artificial Intelligence
    • Blockchain Tech
    • Precision Medicine
    • Telehealth
    • Wearables
  • Startups
  • Value-Based Care
    • Accountable Care
    • Medicare Advantage

Connect

Subscribe to HIT Consultant Media

Latest insightful articles delivered straight to your inbox weekly

Copyright © 2025. HIT Consultant Media. All Rights Reserved. Privacy Policy |